Scientists showed a relapsed and refractory thyroid cancer patient treated with thyroid-stimulating hormone receptor + (TSHR) CD19 CAR-T, a combination of two 2nd generation CAR-T molecules targeting both TSHR and CD19.
[Experimental Hematology & Oncology]